chronic stable angina pectoris of coronary heart disease
Conditions
Interventions
experiment group:Liqihuoxue Diwan
Sponsors
Shanghai Changzheng hospital
Eligibility
Sex/Gender
All
Age
40 Years to 100 Years
Inclusion criteria
Inclusion criteria: 1. Aged more than 40 years old, male and female; 2. Patients diagnosed as Coronary heart disease with chronic stable angina pectoris: (1) Diagnostic criteria TRTHE GUIDELINE FOR THE DIAGNOSIS AND TREATMENT OF THE CHRONIC STABLE ANGINA promulgated in 2007 by Chinese Society of Cardiology; (2) Patients consistent with chronic stable angina pectoris and one of following Objective diagnostic evidence, as 1) A clear case history of old myocardial infarction and ST-T changes in ECG; 2) Previous?coronary arteriongraphy or CTA result indicated that at least one coronary artery stenosis and lumen stenosis >50%; 3) Previous radionuclide?studies diagnosed as coronary heart disease; 3. Not participate in other drug clinical trials in the past 4 weeks; 4. No using Chinese patent medicine preparation approved by CFDA which has Indications of coronary heart disease and /or angina pectoris in at least 2 weeks; 5. Laboratory examination in accordance with the following standards: (l) Routine blood test: HB=95g/LANC=2.0×10^9/LPLT=100×10^9/L; (2) Liver function test: STB and CB=ULN×1.5, ALT and AST=ULN×3.0; (3) Renal function test: Cr=ULN, BUN=ULN; 6. Patients sign the informed consent voluntarily.
Exclusion criteria
Exclusion criteria: 1. Acute myocardial infarction, unstable angina; 2. Serious cardiopulmonary dysfunction (NYHA = III), severe arrhythmia (atrial fibrillation,Paroxysmal atrial flutter, ventricular tachycardia); 3. Non coronary heart disease angina, such as aortic valve disease, aortic dissection, hypertrophy type Cardiomyopathy, hyperthyroidism, and uncontrolled hypertension (SBP = 160mmHg,DBP = 100mmHg); 4. At the same time combined with some dieases whch the investigators believe will interfere with the objective evaluation,such as severe neurosis, climacteric syndrome, cervical spondylosis, esophageal hiatal hernia, biliary and esophageal chest pain and so on; 5. Known or suspected of allergies of the study drug or allergic constitution; 6. Female who are ready to pregnant, pregnant, breast-feeding or disagree to use contraceptive measures during the medication; 7. The situations that investigators believe do not conform to the study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Safety; | — |
Secondary
| Measure | Time frame |
|---|---|
| the stopping and reducing rate of Nitroglycerin Sublingual Tablets ;ECG; | — |
Countries
China
Contacts
Public ContactDonghu Sui
Guizhou Yibai Pharmaceutical Co., Ltd.
Outcome results
None listed